FCGR1A and neoplasm: Initially, the presence of CD4 and CD56 should be evaluated since only 8% of BPDCNs are negative for these, and their mere presence without other specific lineage markers such as CD19, cCD3, MPO, CD14, or CD64 with high HLA-DR should alert about the possibility of this type of neoplasm [1].